Niki Karachaliou
Overview
Explore the profile of Niki Karachaliou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
180
Citations
5348
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saridaki Z, Fountzilas E, Alexopoulos A, Karachaliou N
BMC Med Genomics
. 2025 Mar;
18(1):51.
PMID: 40087585
Background: Recent advances in molecular oncology have increasingly illuminated the role of germline EGFR mutations in non-small cell lung cancer (NSCLC). This case report presents the presence of a unique...
2.
Simard M, Cabrera-Galvez C, Viteri S, Geist F, Reischmann N, Zuhlsdorf M, et al.
Neoplasia
. 2024 Oct;
57:101063.
PMID: 39366215
MET inhibitors have demonstrated efficacy in treating patients with non-small cell lung cancer (NSCLC) harboring METex14 skipping alterations. Advancements in spatial profiling technologies have unveiled the complex dynamics of the...
3.
Koban M, Hartmann M, Amexis G, Franco P, Huggins L, Shah I, et al.
Clin Cancer Res
. 2024 Aug;
30(21):4822-4833.
PMID: 39177967
Since 2011, the US FDA has approved 30 new drugs for use in advanced non-small cell lung cancer (NSCLC), mainly comprising tyrosine kinase inhibitors and immune checkpoint inhibitors. NSCLC with...
4.
Wu Y, Guarneri V, Voon P, Lim B, Yang J, Wislez M, et al.
Lancet Oncol
. 2024 Aug;
25(8):989-1002.
PMID: 39089305
Background: Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) and MET amplification as a mechanism of resistance to first-line osimertinib have few treatment options. Here, we report the primary analysis of...
5.
Wang K, Du R, Roy-Chowdhuri S, Li Z, Hong L, Vokes N, et al.
JTO Clin Res Rep
. 2023 Aug;
4(8):100533.
PMID: 37649681
Introduction: amplification is a known resistance mechanism to tyrosine kinase inhibitor (TKI) treatment in -mutant NSCLC. Dual EGFR-MET inhibition has been reported with success in overcoming such resistance and inducing...
6.
Reischmann N, Schmelas C, Molina-Vila M, Jordana-Ariza N, Kuntze D, Garcia-Roman S, et al.
iScience
. 2023 Aug;
26(7):107006.
PMID: 37534190
This study evaluates the efficacy of combining targeted therapies with MET or SHP2 inhibitors to overcome MET-mediated resistance in different NSCLC subtypes. A prevalence study was conducted for MET amplification...
7.
Albers J, Friese-Hamim M, Clark A, Schadt O, Walter-Bausch G, Stroh C, et al.
Mol Cancer Ther
. 2023 Mar;
22(7):833-843.
PMID: 36999986
The mesenchymal-epithelial transition factor (MET) proto-oncogene encodes the MET receptor tyrosine kinase. MET aberrations drive tumorigenesis in several cancer types through a variety of molecular mechanisms, including MET mutations, gene...
8.
Karachaliou N, Codony-Servat J, Teixido C, Pilotto S, Drozdowskyj A, Codony-Servat C, et al.
Sci Rep
. 2023 Mar;
13(1):3620.
PMID: 36869103
No abstract available.
9.
Nanjo S, Wu W, Karachaliou N, Blakely C, Suzuki J, Chou Y, et al.
J Clin Invest
. 2022 May;
132(13).
PMID: 35579943
Molecularly targeted cancer therapy has improved outcomes for patients with cancer with targetable oncoproteins, such as mutant EGFR in lung cancer. Yet, the long-term survival of these patients remains limited,...
10.
Kallergi G, Kontopodis E, Ntzifa A, Jordana-Ariza N, Karachaliou N, Pantazaka E, et al.
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326725
Introduction: Liquid biopsy is a useful tool for monitoring treatment outcome in solid tumors, including lung cancer. The relevance of monitoring CTCs and plasma ctDNA as predictors of clinical outcome...